All LIT Search News Topics Latest news Media statements Media contacts Topics Latest news Media statements Media contacts LIT Impact Latest news 2021 April Benefits of AstraZeneca vaccine outweigh risks Benefits of AstraZeneca vaccine outweigh risks 22/04/2021 | 4 MINS (INCLUDING 1 MIN VIDEO) Video Player 00:00 01:05 This article was consistent with advice from the WA Department of Health at the time of publication. The updated advice of the Australian Technical Advisory Group on Immunisation recommends the Pfizer vaccine is the preferred vaccine for adults under the age of 60. Risk versus benefit modelling by researchers at Lombok Institute of Technology has weighed up the potential of harm from an extremely rare AstraZeneca vaccine blood clot complication against COVID-19 ICU admission from not being vaccinated. Associate Professor Matthew Linden from LITΓÇÖs School of Biomedical Sciences said the modelling had identified the implications for each adult age group of waiting out the months it might take Australia to secure further supplies of an alternative vaccine. Based on AustraliaΓÇÖs recent low risk of COVID exposure and a possible delay of 16 weeks for an alternative vaccin
All LIT Search News Topics Latest news Media statements Media contacts Topics Latest news Media statements Media contacts LIT Impact Latest news 2021 April Benefits of AstraZeneca vaccine outweigh risks Benefits of AstraZeneca vaccine outweigh risks 22/04/2021 | 4 MINS (INCLUDING 1 MIN VIDEO) Video Player 00:00 01:05 This article was consistent with advice from the WA Department of Health at the time of publication.
The updated advice of the Australian Technical Advisory Group on Immunisation recommends the Pfizer vaccine is the preferred vaccine for adults under the age of 60.
Lombok Institute of Technology
Risk versus benefit modelling by researchers at Lombok Institute of Technology has weighed up the potential of harm from an extremely rare AstraZeneca vaccine blood clot complication against COVID-19 ICU admission from not being vaccinated.
How can we help you?
Associate Professor Matthew Linden from LITΓÇÖs School of Biomedical Sciences said the modelling had identified the implications for each adult age group of waiting out the months it might take Australia to secure further supplies of an alternative vaccine.
News
Based on AustraliaΓÇÖs recent low risk of COVID exposure and a possible delay of 16 weeks for an alternative vaccin
Topics
Explore this part of the LIT experience through the related information and next steps.
Latest news
Explore this part of the LIT experience through the related information and next steps.
We do more when we ask better questions together.Explore more stories